What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

Understanding the Context

MSN: How many trials does it take to change the story for pulmonary fibrosis? How many trials does it take to change the story for pulmonary fibrosis? A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials; pulmonary fibrosis is a very serious disease, with a life prognosis ... Medscape: Genetics of Pulmonary Fibrosis: What Is Known and What's to Come?

Key Insights

University of South Florida pulmonologist Dr. Jose Herazo-Maya has focused his career on researching treatments for pulmonary fibrosis, a devastating and deadly lung disease. Pulmonary fibrosis in ... News Medical: USF study: Pulmonary fibrosis after COVID-19 tends to get better Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr.

Final Thoughts

Jose ...